Equity Profile

VERA

Vera Therapeutics, Inc.

Health CareBiotechnology$2.5B

May7Thu

Post-Earnings Recap

ReportedQ1-2026Pre-Market7:30 AM EDT

Vera Therapeutics Misses on EPS, Stock Down 1.95%

Metric	Actual	Expected	Surprise
EPS	$-1.69	$-1.37	-34.13%
Revenue	$0M	$0M	N/A

management commentary, guidance changes, and full analysis available with Pro.

Vera Therapeutics Misses on EPS, Stock Down 1.95%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-1.69	$-1.37	-34.13%
Revenue	$0M	$0M	N/A

Management Commentary

Tone: Unknown

No transcript is on record for the earnings call, so the analysis is based solely on numerical results.

What It Means

Vera Therapeutics reported a larger-than-expected loss per share, which contributed to a decline in the stock price by 1.95%. Investors may be concerned about the company's financial performance given the EPS miss. The lack of revenue and guidance updates adds to the uncertainty surrounding the company's future prospects.

Company Snapshot

Vera Therapeutics, Inc. is a biotechnology company focused on developing therapies for serious diseases....

Key Metrics to Watch

EPS

Earnings per share is a critical measure of profitability and will indicate how well the company is managing its expenses.

$-1.37

Revenue

Although no revenue is expected this quarter, any updates on product development or partnerships could signal future revenue potential.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Vera Therapeutics, Inc. is a biotechnology company focused on developing therapies for serious diseases. With a market cap of $3 billion, it operates in the health care sector, which is seeing increased attention due to advancements in medical treatments and the ongoing demand for innovative solutions.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

Avg EPS Surprise

-46.67%

Avg Stock Reaction

-2.15%

Last Quarter Recap

In Q4 2025, Vera Therapeutics reported an EPS of $-4.66, significantly missing expectations. The stock reacted positively, gaining 1.61% the following day despite the disappointing results.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are expecting another challenging quarter for Vera, with a consensus EPS of $-1.37. Investors will be closely monitoring any signs of progress in product development.

Bull Case

If Vera can demonstrate advancements in its drug pipeline or secure partnerships, it could lead to a positive shift in investor sentiment and stock performance.

Bear Case

Continued losses and lack of revenue could raise concerns about the company's viability and lead to further stock declines.

Key Metrics to Watch

EPS

$-1.37

Earnings per share is a critical measure of profitability and will indicate how well the company is managing its expenses.

Revenue

$0M

Although no revenue is expected this quarter, any updates on product development or partnerships could signal future revenue potential.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Vera provide any updates on its drug pipeline or potential partnerships?

Investors are keen to understand the company's future revenue potential, especially given the lack of expected revenue this quarter.

How does management plan to address the significant EPS losses reported in previous quarters?

Management's strategy for reducing losses will be critical for investor confidence and could influence stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Vera's drug pipeline to yield results sooner than anticipated, particularly in light of recent industry trends.

Supporting Evidence

The options market indicates a high expected move, suggesting that traders foresee significant developments.

Insider selling may reflect a strategic repositioning rather than a lack of confidence in the company's future.

Key Risk

If any unexpected positive news about the drug pipeline emerges, it could significantly alter the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for future growth against the backdrop of ongoing losses, making this quarter's results particularly pivotal.

Bull Confirmed If

A narrower EPS loss than the consensus of $-1.37 could signal improved cost management.

Bear Confirmed If

An EPS loss greater than $-1.37 would reinforce concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±10.98%

Historical Avg

±3.5%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±9.8% while VERA has averaged ±3.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

45.0%

Calls (29K)P/C Ratio: 0.03Puts (3K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.0M

22,951 sh

1 insider

Net

$1.0M

Net selling

Most Active Insiders· 3 open-market trades

PRESIDENT AND CEOFordyce Marshall
$1.0M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Vera beats EPS expectations, history suggests the stock could rise by an average of 3.1%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A significant miss could lead to a decline in stock price, with historical patterns indicating an average drop of 2.18%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the drug pipeline and any potential partnerships.
2Management's strategy for addressing ongoing losses.
3Any commentary on market conditions affecting the biotechnology sector.
4Insights into future revenue generation plans.
5Details on cost management efforts and operational efficiencies.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

The Marzetti Company

Company Snapshot

Vera Therapeutics, Inc. is a biotechnology company focused on developing therapies for serious diseases....

Key Metrics to Watch

EPS

Earnings per share is a critical measure of profitability and will indicate how well the company is managing its expenses.

$-1.37

Revenue

Although no revenue is expected this quarter, any updates on product development or partnerships could signal future revenue potential.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

Avg EPS Surprise

-46.67%

Avg Stock Reaction

-2.15%

Last Quarter Recap

In Q4 2025, Vera Therapeutics reported an EPS of $-4.66, significantly missing expectations. The stock reacted positively, gaining 1.61% the following day despite the disappointing results.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are expecting another challenging quarter for Vera, with a consensus EPS of $-1.37. Investors will be closely monitoring any signs of progress in product development.

Bull Case

If Vera can demonstrate advancements in its drug pipeline or secure partnerships, it could lead to a positive shift in investor sentiment and stock performance.

Bear Case

Continued losses and lack of revenue could raise concerns about the company's viability and lead to further stock declines.

Key Metrics to Watch

EPS

$-1.37

Earnings per share is a critical measure of profitability and will indicate how well the company is managing its expenses.

Revenue

$0M

Although no revenue is expected this quarter, any updates on product development or partnerships could signal future revenue potential.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Vera provide any updates on its drug pipeline or potential partnerships?

Investors are keen to understand the company's future revenue potential, especially given the lack of expected revenue this quarter.

How does management plan to address the significant EPS losses reported in previous quarters?

Management's strategy for reducing losses will be critical for investor confidence and could influence stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Vera's drug pipeline to yield results sooner than anticipated, particularly in light of recent industry trends.

Supporting Evidence

The options market indicates a high expected move, suggesting that traders foresee significant developments.

Insider selling may reflect a strategic repositioning rather than a lack of confidence in the company's future.

Key Risk

If any unexpected positive news about the drug pipeline emerges, it could significantly alter the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for future growth against the backdrop of ongoing losses, making this quarter's results particularly pivotal.

Bull Confirmed If

A narrower EPS loss than the consensus of $-1.37 could signal improved cost management.

Bear Confirmed If

An EPS loss greater than $-1.37 would reinforce concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±10.98%

Historical Avg

±3.5%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±9.8% while VERA has averaged ±3.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

45.0%

Calls (29K)P/C Ratio: 0.03Puts (3K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.0M

22,951 sh

1 insider

Net

$1.0M

Net selling

Most Active Insiders· 3 open-market trades

PRESIDENT AND CEOFordyce Marshall
$1.0M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Vera beats EPS expectations, history suggests the stock could rise by an average of 3.1%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A significant miss could lead to a decline in stock price, with historical patterns indicating an average drop of 2.18%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the drug pipeline and any potential partnerships.
2Management's strategy for addressing ongoing losses.
3Any commentary on market conditions affecting the biotechnology sector.
4Insights into future revenue generation plans.
5Details on cost management efforts and operational efficiencies.